Samsung Bioepis receives positive evaluations for ‘Flixabi’ from CHMP
On the 2nd, Samsung Bioepis announced it received positive opinions from the European Medicines Agency(EMA) and the Committee for Medicinal Products for Human Use(CHMP) for its autoimmune disease treatment Flixabi.
Flixabi, a biosimilar of Remicade(infliximab) that is similar to Lenflexis approv...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
